NYSE Content Update: Grindr Reports 28% Full Year Revenue Growth in Q4 Earnings
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK,…
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated…
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
February 24, 2026 16:30 ET | Source: Cardiff Oncology, Inc. Reported positive…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 17, 2026 18:22 ET | Source: BridgeBio Pharma, Inc. PALO ALTO,…
Inventiva reports preliminary 2025 fiscal year financial results
Cash and cash equivalents at €99.3 million, and €131.6 million in short-term…
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million…
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
Exceeding latest 2025 guidance following a strong performance from both commercial arms…
MEXC Reports 2.35 Million Users Across AI Trading Suite in First Six Months
VICTORIA, Seychelles, Feb. 10, 2026 /PRNewswire/ -- MEXC, the fastest-growing global cryptocurrency exchange,…
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
February 11, 2026 06:00 ET | Source: Upstream Bio – Verekitug provided…
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today…
